Pharma firm Granules India today said its Gagillapur facility in Hyderabad has completed USFDA inspection without any observations.
"The company's Gagillapur facility located in Hyderabad, Telangana... Has successfully completed US FDA inspection without any observations," Granules India said in a BSE filing.
"This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)."
The stock of Granules India was trading 2.29 per cent higher at Rs 122.75 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
